| Primary |
| Infection |
14.4% |
| Constipation |
9.6% |
| Drug Use For Unknown Indication |
9.2% |
| Sepsis |
8.5% |
| Hypertension |
7.2% |
| Anaesthesia |
6.5% |
| Prophylaxis |
5.5% |
| Sedation |
5.0% |
| Bacterial Infection |
4.8% |
| Fungal Infection |
4.8% |
| Lung Infection |
4.8% |
| Cardiac Disorder |
3.6% |
| Haemorrhage |
2.6% |
| Anticoagulant Therapy |
2.4% |
| Bladder Spasm |
2.4% |
| Nausea |
2.4% |
| Aortic Valve Replacement |
1.7% |
| Coronary Artery Bypass |
1.7% |
| Antiplatelet Therapy |
1.5% |
| Renal Failure |
1.5% |
|
| Ureterostomy Site Discomfort |
11.6% |
| Shock |
8.1% |
| Ventricular Failure |
8.1% |
| Renal Failure |
7.0% |
| Thrombosis |
7.0% |
| Intracardiac Thrombus |
5.8% |
| Renal Failure Acute |
5.8% |
| Post Procedural Complication |
4.7% |
| Thrombocytopenia |
4.7% |
| Urine Output Decreased |
4.7% |
| Ventricular Fibrillation |
4.7% |
| Ventricular Hypokinesia |
4.7% |
| Pulmonary Thrombosis |
3.5% |
| Right Ventricular Failure |
3.5% |
| Thrombotic Thrombocytopenic Purpura |
3.5% |
| Vasculitis |
3.5% |
| Coronary Artery Occlusion |
2.3% |
| Device Alarm Issue |
2.3% |
| Myocardial Ischaemia |
2.3% |
| Pulmonary Embolism |
2.3% |
|
| Secondary |
| Drug Use For Unknown Indication |
37.0% |
| Cardiac Disorder |
12.9% |
| Anaesthesia |
12.5% |
| Anticoagulant Therapy |
6.7% |
| Antiplatelet Therapy |
5.5% |
| Thrombolysis |
5.5% |
| Aortic Valve Replacement |
3.1% |
| Coagulation Time Abnormal |
2.5% |
| Coagulopathy |
1.8% |
| Haemorrhage Control |
1.8% |
| Post Procedural Haemorrhage |
1.8% |
| Endocarditis |
1.6% |
| Bacteraemia |
1.2% |
| Heparin Neutralisation Therapy |
1.2% |
| Cardiac Failure Congestive |
1.0% |
| Haemorrhage Prophylaxis |
0.8% |
| Thoracic Operation |
0.8% |
| Thrombosis Prophylaxis |
0.8% |
| Heart Valve Replacement |
0.6% |
| Hypotonia |
0.6% |
|
| Ventricular Failure |
22.0% |
| Intracardiac Thrombus |
10.0% |
| Device Alarm Issue |
8.0% |
| Respiratory Failure |
8.0% |
| Cardiac Failure Congestive |
6.0% |
| Renal Failure Acute |
6.0% |
| Right Ventricular Failure |
6.0% |
| Tachycardia |
6.0% |
| Ventricular Hypokinesia |
6.0% |
| Myocardial Ischaemia |
4.0% |
| Therapy Non-responder |
4.0% |
| Vena Cava Thrombosis |
4.0% |
| Ventricular Fibrillation |
4.0% |
| Hyperkalaemia |
2.0% |
| Obstructive Airways Disorder |
2.0% |
| Thrombotic Microangiopathy |
2.0% |
|
| Concomitant |
| Product Used For Unknown Indication |
20.0% |
| Prophylaxis |
9.0% |
| Coronary Artery Bypass |
7.0% |
| Drug Use For Unknown Indication |
6.8% |
| Ill-defined Disorder |
5.9% |
| Haemorrhage |
5.6% |
| Hypertension |
4.5% |
| Rheumatoid Arthritis |
4.5% |
| Sedation |
4.5% |
| Cardiopulmonary Bypass |
3.9% |
| Thrombosis Prophylaxis |
3.7% |
| Anti-infective Therapy |
3.4% |
| Myocardial Infarction |
3.4% |
| Infection Prophylaxis |
3.1% |
| Liver Transplant |
2.8% |
| Anticoagulant Therapy |
2.5% |
| Lung Transplant |
2.5% |
| Coronary Artery Disease |
2.3% |
| Post Procedural Haemorrhage |
2.3% |
| Premedication |
2.3% |
|
| Renal Failure |
12.9% |
| Wound Secretion |
9.7% |
| Unevaluable Event |
8.1% |
| Cerebrovascular Accident |
6.5% |
| Wound Dehiscence |
6.5% |
| Depression |
4.8% |
| Rash |
4.8% |
| Thrombosis |
4.8% |
| Troponin I Increased |
4.8% |
| Ventricular Tachycardia |
4.8% |
| Anhedonia |
3.2% |
| Atrial Fibrillation |
3.2% |
| Catheter Related Complication |
3.2% |
| Death |
3.2% |
| Drug Effect Decreased |
3.2% |
| Ileus |
3.2% |
| Injury |
3.2% |
| Multi-organ Failure |
3.2% |
| Pneumothorax |
3.2% |
| Post Procedural Cellulitis |
3.2% |
|
| Interacting |
| Acute Promyelocytic Leukaemia |
50.0% |
| Drug Use For Unknown Indication |
50.0% |
|
| Respiratory Failure |
50.0% |
| White Blood Cell Count Decreased |
50.0% |
|
